- Mural Oncology plc press release (NASDAQ:MURA): Q1 GAAP EPS of -$1.84.
- As of March 31, 2024, cash, cash equivalents, and marketable securities were $231.7 million.
-
Financial Guidance
- The company reaffirms guidance that its cash, cash equivalents, and marketable securities are expected to fund its operations into the fourth quarter of 2025.
- As noted in the 2023 year-end financial results press release, Mural anticipates reporting lower year-over-year operating expenses in 2024. Also, management forecasts higher operating expenses in 2024 versus 2025 due to the timing of clinical trial expenses.
Mural Oncology GAAP EPS of -$1.84; reaffirms financial guidance
